Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 377

1.

Rare case of meningeal tuberculoma mimicking meningioma in term pregnancy and its management.

Singh S, Patnaik A, Sahu RN, Jena SS, Mohakud S, Purkait S.

Surg Neurol Int. 2018 Sep 3;9:178. doi: 10.4103/sni.sni_271_17. eCollection 2018. No abstract available.

2.

24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Chih-Hsin Yang J, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller S, Gandhi L.

J Thorac Oncol. 2018 Aug 20. pii: S1556-0864(18)30942-0. doi: 10.1016/j.jtho.2018.08.004. [Epub ahead of print]

PMID:
30138764
3.

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.

Papadopoulos KP, Ben-Ami E, Patnaik A, Trone D, Li J, Demetri GD.

BMC Cancer. 2018 Aug 6;18(1):790. doi: 10.1186/s12885-018-4692-z.

4.

Discovery of 1-((6-Aminopyridin-3-yl)Methyl)-3-(4-Bromophenyl)Urea as a Potent, Irreversible Myeloperoxidase Inhibitor.

Marro ML, Patterson AW, Lee L, Deng L, Reynolds A, Ren X, Axford L, Patnaik A, Hollis-Symynkywicz M, Casson N, Custeau D, Ames L, Loi S, Zhang L, Honda T, Blank J, Harrison TJ, Papillon JPN, Hamann LG, Marcinkeviciene J, Regard JB.

J Pharmacol Exp Ther. 2018 Oct;367(1):147-154. doi: 10.1124/jpet.118.248435. Epub 2018 Aug 3.

PMID:
30076263
5.

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D.

Cancer Chemother Pharmacol. 2018 Sep;82(3):419. doi: 10.1007/s00280-018-3641-5.

PMID:
30014222
6.

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Patnaik A, Gordon M, Tsai F, Papadopoulous K, Rasco D, Beeram SM, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D.

Cancer Chemother Pharmacol. 2018 Sep;82(3):407-418. doi: 10.1007/s00280-018-3623-7. Epub 2018 Jun 20. Erratum in: Cancer Chemother Pharmacol. 2018 Jul 16;:.

7.

Carbon Nanosheets by Morphology-Retained Carbonization of Two-Dimensional Assembled Anisotropic Carbon Nanorings.

Mori T, Tanaka H, Dalui A, Mitoma N, Suzuki K, Matsumoto M, Aggarwal N, Patnaik A, Acharya S, Shrestha LK, Sakamoto H, Itami K, Ariga K.

Angew Chem Int Ed Engl. 2018 Jul 26;57(31):9679-9683. doi: 10.1002/anie.201803859. Epub 2018 Jul 5.

PMID:
29917300
8.

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.

Finn RS, Ahn DH, Javle MM, Tan BR Jr, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS.

Invest New Drugs. 2018 May 22. doi: 10.1007/s10637-018-0600-2. [Epub ahead of print]

PMID:
29785570
9.

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.

Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P.

Ann Oncol. 2018 Jul 1;29(7):1561-1568. doi: 10.1093/annonc/mdy171.

PMID:
29726923
10.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Apr 23. doi: 10.1158/1078-0432.CCR-17-2386. [Epub ahead of print]

PMID:
29685882
11.

A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.

Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, Bullock A, Rock E, Elekes A, Lin C, Kostic D, Ohi N, Rasco D, Papadopoulos KP, Patnaik A, Smith L, Cote GM.

Oncologist. 2018 Jun;23(6):658-e72. doi: 10.1634/theoncologist.2017-0325. Epub 2018 Mar 6.

12.

Nondystrophic holocord intramedullary lipoma: an uncommon case.

Bansal S, Sahu RN, Patnaik A.

Childs Nerv Syst. 2018 Apr;34(4):591-592. doi: 10.1007/s00381-018-3757-2. Epub 2018 Feb 19. No abstract available.

PMID:
29460061
13.

Neutrophils and anti-cancer immunity: a paradigm shift in cancer immunotherapy.

Sturey R, Patnaik A.

Oncoscience. 2017 Nov 28;4(11-12):164-165. doi: 10.18632/oncoscience.378. eCollection 2017 Nov. No abstract available.

14.

Development of Thrombotic Thrombocytopenic Purpura in Association With the Monoclonal Antibody, Golimumab, Used to Treat Rheumatoid Arthritis, in a Case With Literature Review.

Cepeda J, Liedke C, Patnaik A, Yao Q.

J Clin Rheumatol. 2018 Jun;24(4):229-231. doi: 10.1097/RHU.0000000000000684. No abstract available.

PMID:
29293116
15.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS.

J Clin Oncol. 2018 Jun 10;36(17):1668-1674. doi: 10.1200/JCO.2017.75.6270. Epub 2017 Dec 28.

PMID:
29283791
16.

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Goldman JW, Rosen LS, Tolcher AW, Papadopoulos K, Beeram M, Shi P, Pitou C, Bell R, Kulanthaivel P, Zhang X, Fink A, Chan EM, Shahir A, Farrington D, Patnaik A.

Invest New Drugs. 2018 Aug;36(4):629-637. doi: 10.1007/s10637-017-0532-2. Epub 2017 Dec 1.

17.

All Fiber-Coupled OH Planar Laser-Induced-Fluorescence (OH-PLIF)-Based Two-Dimensional Thermometry.

Hsu PS, Jiang N, Patnaik AK, Katta V, Roy S, Gord JR.

Appl Spectrosc. 2018 Apr;72(4):604-610. doi: 10.1177/0003702817744519. Epub 2017 Nov 28.

PMID:
29148279
18.

FLEET velocimetry for combustion and flow diagnostics.

DeLuca NJ, Miles RB, Jiang N, Kulatilaka WD, Patnaik AK, Gord JR.

Appl Opt. 2017 Nov 1;56(31):8632-8638. doi: 10.1364/AO.56.008632.

PMID:
29091674
19.

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, Hall T, Schwartz B, Wang Y, Kazakin J, Shaib WL.

Br J Cancer. 2017 Nov 21;117(11):1592-1599. doi: 10.1038/bjc.2017.330. Epub 2017 Oct 3.

20.

Extensive intracranial calcification of pseudo-TORCH syndrome with features of Dandy-Walker malformation.

Patnaik A, Mishra SS, Das S.

Asian J Neurosurg. 2017 Jul-Sep;12(3):541-543. doi: 10.4103/1793-5482.145162.

21.

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.

Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, Thall AD, Pathan N, Schmidt EV, Chow LQM.

Clin Cancer Res. 2017 Sep 15;23(18):5349-5357. doi: 10.1158/1078-0432.CCR-17-1243. Epub 2017 Jun 20.

22.

Structure and Dynamics of a N-Methylfulleropyrrolidine-Mediated Gold Nanocomposite: A Spectroscopic Ruler.

Sutradhar S, Patnaik A.

ACS Appl Mater Interfaces. 2017 Jul 5;9(26):21921-21932. doi: 10.1021/acsami.7b02640. Epub 2017 Jun 20.

PMID:
28593769
23.

Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.

Piizzi G, Parker DT, Peng Y, Dobler M, Patnaik A, Wattanasin S, Liu E, Lenoir F, Nunez J, Kerrigan J, McKenney D, Osborne C, Yu D, Lanieri L, Bojkovic J, Dzink-Fox J, Lilly MD, Sprague ER, Lu Y, Wang H, Ranjitkar S, Xie L, Wang B, Glick M, Hamann LG, Tommasi R, Yang X, Dean CR.

J Med Chem. 2017 Jun 22;60(12):5002-5014. doi: 10.1021/acs.jmedchem.7b00377. Epub 2017 Jun 9.

PMID:
28549219
24.

Effect of Selected Yogic Practices on Pain and Disability in Patients with Lumbar Spondylitis.

Manik RK, Mahapatra AK, Gartia R, Bansal S, Patnaik A.

Int J Yoga. 2017 May-Aug;10(2):81-87. doi: 10.4103/0973-6131.205516.

25.

Infective Endocarditis of the Left Main to Right Atrial Coronary Cameral Fistula.

Mishra RC, Barik R, Patnaik AN.

J Cardiovasc Echogr. 2016 Oct-Dec;26(4):123-126. doi: 10.4103/2211-4122.192178.

26.

Intraventricular glioblastoma multiforme mimicking meningioma and review of the literature.

Patnaik A, Mishra SS, Senapati SB.

Asian J Neurosurg. 2017 Jan-Mar;12(1):75-77. doi: 10.4103/1793-5482.145104.

27.

Spontaneous extradural and subgaleal hematoma: A rare neurosurgical crisis of sickle cell disease.

Mishra SS, Senapati SB, Gouda AK, Behera SK, Patnaik A.

Asian J Neurosurg. 2017 Jan-Mar;12(1):47-50. doi: 10.4103/1793-5482.144177.

28.

Unusual Nonemissive Behavior of Rubrene J-Aggregates: A Rare Violation.

Aggarwal N, Patnaik A.

J Phys Chem B. 2017 Apr 13;121(14):3190-3201. doi: 10.1021/acs.jpcb.7b02072. Epub 2017 Mar 30.

PMID:
28334526
29.

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.

Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC, Elemento O, Novak J, Thornley TB, Asara JM, Montaser L, Timmons JJ, Morgan TM, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP, Cantley LC.

Cancer Discov. 2017 Jul;7(7):750-765. doi: 10.1158/2159-8290.CD-16-0778. Epub 2017 Mar 8.

30.

Regio-selective lipase catalyzed hydrolysis of oxanorbornane-based sugar-like amphiphiles at air-water interface: A polarized FT-IRRAS study.

Sarangi NK, Ganesan M, Muraleedharan KM, Patnaik A.

Chem Phys Lipids. 2017 Apr;204:25-33. doi: 10.1016/j.chemphyslip.2017.02.004. Epub 2017 Feb 22.

PMID:
28235449
31.

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.

Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, Emancipator K, Roach C, Rizvi NA.

Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008.

PMID:
28168303
32.

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.

Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A.

Br J Cancer. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2.

33.

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

Infante JR, Patnaik A, Verschraegen CF, Olszanski AJ, Shaheen M, Burris HA, Tolcher AW, Papadopoulos KP, Beeram M, Hynes SM, Leohr J, Lin AB, Li LQ, McGlothlin A, Farrington DL, Westin EH, Cohen RB.

Cancer Chemother Pharmacol. 2017 Feb;79(2):315-326. doi: 10.1007/s00280-016-3205-5. Epub 2017 Jan 17.

PMID:
28097385
34.

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.

Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV.

J Clin Oncol. 2017 Jan 20;35(3):352-360. doi: 10.1200/JCO.2016.67.5264. Epub 2016 Nov 21.

35.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O.

J Clin Oncol. 2016 Dec;34(34):4102-4109. Epub 2016 Oct 31.

36.

Sensitivity, stability, and precision of quantitative Ns-LIBS-based fuel-air-ratio measurements for methane-air flames at 1-11 bar.

Hsu PS, Gragston M, Wu Y, Zhang Z, Patnaik AK, Kiefer J, Roy S, Gord JR.

Appl Opt. 2016 Oct 1;55(28):8042-8048. doi: 10.1364/AO.55.008042.

PMID:
27828047
37.

Investigation of titania nanoparticles on behaviour and mechanosensory organ of Drosophila melanogaster.

Sabat D, Patnaik A, Ekka B, Dash P, Mishra M.

Physiol Behav. 2016 Dec 1;167:76-85. doi: 10.1016/j.physbeh.2016.08.032. Epub 2016 Sep 5.

PMID:
27609308
38.

Infective endocarditis caused by Stenotrophomonas maltophilia: A report of two cases and review of literature.

Subhani S, Patnaik AN, Barik R, Nemani L.

Indian Heart J. 2016 Sep;68 Suppl 2:S267-S270. doi: 10.1016/j.ihj.2015.07.048. Epub 2016 Jan 14. Review.

39.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators.

Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.

PMID:
27745820
40.

Recurrence of spinal schwannoma: Is it preventable?

Senapati SB, Mishra SS, Dhir MK, Patnaik A, Panigrahi S.

Asian J Neurosurg. 2016 Oct-Dec;11(4):451.

41.

P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy.

Ramalingam S, Hui R, Gandhi L, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Leighl N, Aggarwal C, Horn L, Patnaik A, Middleton GW, Gubens M, Hellmann M, Soria JC, Lubiniecki GM, Zhang J, Piperdi B, Garon EB.

J Thorac Oncol. 2016 Oct;11(10S):S241-S242. doi: 10.1016/j.jtho.2016.08.110. Epub 2016 Sep 22. No abstract available.

42.

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvresse I, Ramanathan RK.

Ann Oncol. 2016 Oct;27(10):1928-40. doi: 10.1093/annonc/mdw282.

43.

Nuclear and Chloroplast DNA Variation Provides Insights into Population Structure and Multiple Origin of Native Aromatic Rices of Odisha, India.

Roy PS, Rao GJ, Jena S, Samal R, Patnaik A, Patnaik SS, Jambhulkar NN, Sharma S, Mohapatra T.

PLoS One. 2016 Sep 6;11(9):e0162268. doi: 10.1371/journal.pone.0162268. eCollection 2016.

44.

Differentiation and description of aromatic short grain rice landraces of eastern Indian state of Odisha based on qualitative phenotypic descriptors.

Roy PS, Samal R, Rao GJ, Patnaik SS, Jambhulkar NN, Patnaik A, Mohapatra T.

BMC Ecol. 2016 Aug 9;16:36. doi: 10.1186/s12898-016-0086-8.

45.

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.

Patnaik A, Tolcher A, Papadopoulos KP, Beeram M, Rasco D, Werner TL, Bauman JW, Scheuber A, Cox DS, Patel BR, Zhou Y, Hamid M, Schramek D, Sharma S.

Cancer Chemother Pharmacol. 2016 Sep;78(3):491-500. doi: 10.1007/s00280-016-3090-y. Epub 2016 Jul 8.

PMID:
27392790
46.

Considerations for double-hand replantation in a resource-constrained healthcare facility.

Nayak BB, Mohanty N, Patnaik AP, Bal PK.

Indian J Plast Surg. 2016 Jan-Apr;49(1):81-5. doi: 10.4103/0970-0358.182233.

47.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI.

Cancer Discov. 2016 Jul;6(7):740-53. doi: 10.1158/2159-8290.CD-16-0095. Epub 2016 May 23.

48.

Spontaneous leaking craniopharyngioma causing preoperative chemical meningitis.

Patnaik A, Mahapatra AK, Sarkar S, Samal DK.

Surg Neurol Int. 2016 Apr 14;7:41. doi: 10.4103/2152-7806.180466. eCollection 2016. No abstract available.

49.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.

JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. Erratum in: JAMA. 2016 Jun 14;315(22):2472.

PMID:
27092830
50.

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.

Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA, Patnaik A, Fairbrother WJ, Wong H, Budha N, Darbonne WC, Peale F, Mamounas M, Royer-Joo S, Yu R, Portera CC, Infante JR.

Clin Cancer Res. 2016 Sep 15;22(18):4567-73. doi: 10.1158/1078-0432.CCR-16-0308. Epub 2016 Apr 13.

Supplemental Content

Loading ...
Support Center